To access the Live Webcast and CME Surveys please login using your registration email address.
CME Certificates will be issued digitally after Speaker Evaluations and Overall Surveys are completed. Surveys are accessible from this website after logging in with the email address you submitted during registration. Surveys will be available online starting the first day of the symposium. You must complete the process by March 6, 2023 in order to receive your certificate. Certificates will be available online until August 1 and are printable directly from the website.
The AAFP has reviewed 23rd Annual San Diego Heart Failure Symposium for Primary Care & Internal Medicine Physicians and deemed it acceptable for up to 8.75 Live AAFP Prescribed credits. Term of Approval is from 02/10/2023 to 02/11/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP Prescribed credit is accepted by the American Medical Association as
equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's
Recognition Award. When applying for the AMA PRA, Prescribed credit earned
must be reported as Prescribed, not as Category 1.
Statements of credit will be awarded based on the participant's attendance. A statement of credit will be available upon completion of an online evaluation/claim credit form available at:
akhcme.com/230018L
Please claim your credit by March 11, 2023. If you have questions about this CE activity, please contact AKH Inc at byron@akhcme.com
The 23rd Annual San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians on February 10-11, 2023 will provide an up to date review of new and emerging trends in the management of patients with heart failure. The Symposium will highlight the most important areas that relate to patient management and focus on opportunities to implement new knowledge into clinical practice.
Day 1 of the Symposium features Sessions on Strategies for Managing Risk Factors with talks on treating hypertension, hyperlipidemia, diabetes, the role of exercise training and an introduction to a new drug, finerenone for treating patients with Type 2 diabetes and chronic kidney disease, Cardiac Hypertrophy, Amyloidosis and Hypertrophic Cardiomyopathy including talks on management of HFpEF, amyloidosis and hypertrophic cardiomyopathy and on Biomarkers, Pulmonary Arterial Hypertension, Sleep Disordered Breathing, Devices for Detecting Decompensated Heart Failure and Use of DOACs with lectures on all of those topics.
Day 2 with start with a Session on Redefining Heart Failure Classes and Stages/Advances in Therapy with talks focused on new guideline approaches for classifying patients with heart failure and updates on the use ARNIs, SGLT2 inhibitors and newer drugs like omecamtiv mecarbil, vericiguat and finerenone as well as an important lecture on strategies to implement guideline directed therapies. This will be followed by a Session on Special Populations and Advanced Heart Failure Treatments with talks on cardio-oncology, adult congenital heart disease, identifying patients who should be referred to a heart failure specialist and treatment options for patients with advanced heart failure. The final Session on Devices to Prevent, Protect and Treat Patients with Heart Failure will include talks covering a broad range of device therapies that are now being used to complement drug therapy in treating patients with heart failure.
Interwoven with the lectures will be live panel and case discussions as well as extensive Q/A panels in order to allow registrants the opportunity to interact with the internationally renowned Symposium faculty. This will allow us to accomplish our goal of providing cutting edge information in a format that enhances adaption into clinical practice.
This course is designed for cardiologists, internists, primary care physicians, nurses, PA’s, PharmD’s and all other allied healthcare professionals with an interest in heart failure.
At the conclusion of this activity, participants should be able to:
Over five million Americans (two percent of the U.S.) are living with heart failure (HF). An estimated 670,000 new cases of HF are diagnosed each year and this condition is a major cause of morbidity and mortality (80% of men and 70% of women less than 65 years of age who have HF will die within 8 years) and is the number one cause of hospitalizations of the elderly in the U.S. HF is common, but unrecognized and often misdiagnosed. Recent data have shown that drugs and devices that have proven beneficial and are recommended in recent practice guidelines, (HFSA 2010 update of practice guidelines Lindelfield J et al J Cardiac Failure 2010:16; 475) are underutilized (Fonarow GC et al. Circulation 2010;122:585).
Recent information also suggests a significant individual variability in conformity to quality-of-care indicators and clinical outcome of patients with HF and a substantial gap in overall performance. In addition, according to a study analyzing the quality of health care in the U.S. on average, patients with heart failure received the recommended quality of care only 64% of the time (heart failure performance measurement set by the ACC/AHA 2010).
Despite important advances in treatment, patients with HF continue to experience unacceptably high rates of morbidity and mortality. This along with the enormous cost of caring for a growing number of HF patients has resulted in increased scrutiny of existing and emerging therapies.
It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.